{"filing":{"accession_number":"0001193125-26-274258","cik":"0001088856","ticker":"CORT","company_name":"CORCEPT THERAPEUTICS INC","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"d159941d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1088856/000119312526274258/d159941d8k.htm"},"events":[{"id":11600,"run_id":10188,"accession_number":"0001193125-26-274258","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"The Company resubmitted a New Drug Application (NDA) to the FDA for relacorilant, a treatment for Cushing's syndrome. This is a material regulatory milestone for a biopharmaceutical company, as NDA resubmission represents progress toward potential commercialization of a key product candidate. However, it does not fit neatly into the more specific event categories (e.g., it is not an earnings release, M\u0026A activity, or executive change), making \"other_material\" the most appropriate classification.","company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","filing_date":"2026-06-17","submitted_at":null,"items":[{"id":8235,"accession_number":"0001193125-26-274258","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The Company resubmitted a New Drug Application (NDA) to the FDA for relacorilant, a treatment for Cushing's syndrome. This is a material regulatory milestone for a biopharmaceutical company, as NDA resubmission represents progress toward potential commercialization of a key product candidate. However, it does not fit neatly into the more specific event categories (e.g., it is not an earnings release, M\u0026A activity, or executive change), making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:38:06.471009+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8235,"accession_number":"0001193125-26-274258","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The Company resubmitted a New Drug Application (NDA) to the FDA for relacorilant, a treatment for Cushing's syndrome. This is a material regulatory milestone for a biopharmaceutical company, as NDA resubmission represents progress toward potential commercialization of a key product candidate. However, it does not fit neatly into the more specific event categories (e.g., it is not an earnings release, M\u0026A activity, or executive change), making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:38:06.471009+00:00","company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","filing_date":"2026-06-17"}]}